Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Orencia (abatacept) is a selective T-cell costimulation modulator, a fusion protein that blocks the activation of T-cells involved in autoimmune inflammation. It is available as both an intravenous infusion and a subcutaneous injection.
Orencia is FDA-approved for moderately to severely active rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in patients 2 years and older, and for the prophylaxis of acute graft-versus-host disease (combined with a calcineurin inhibitor and methotrexate) in patients 2 years and older undergoing hematopoietic stem cell transplantation.
Abatacept binds to CD80/CD86 on antigen-presenting cells, blocking the CD28-mediated costimulation signal T-cells need for full activation, thereby reducing the inflammatory immune response.
For rheumatoid arthritis, Orencia is typically given as a weekly subcutaneous injection, with or without an initial intravenous loading dose. For acute GVHD prophylaxis, it is administered intravenously in combination with a calcineurin inhibitor and methotrexate. Exact dosing and weight-based calculations are determined by the treating specialist.
Orencia requires monitoring for several important safety considerations common to immunomodulating therapies.
Increased risk of serious infections, including tuberculosis and opportunistic infections. Screen for latent TB before starting treatment.
Concomitant use with other biologic DMARDs or JAK inhibitors is not recommended due to increased infection risk without added benefit.
Use with caution in patients with COPD, as increased incidence of adverse respiratory events has been observed.
Anaphylaxis and hypersensitivity reactions can occur, particularly with IV infusion.
Avoid concurrent use of live vaccines during treatment and for a defined period after discontinuation.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Orencia (abatacept) received initial FDA approval in 2005 and is manufactured by Bristol-Myers Squibb, available in both intravenous and subcutaneous formulations.
Import of Orencia through a Named Patient Program requires a valid prescription from the treating rheumatologist or transplant physician, relevant diagnostic and treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Orencia directly from Bristol-Myers Squibb's authorized supply chain to ensure product authenticity and regulatory compliance.
Orencia is sourced through verified, GDP-compliant, cold-chain channels from Bristol-Myers Squibb's authorized supply chain to ensure authenticity and quality.
Orencia should be stored refrigerated at 2°C to 8°C. Do not freeze.
Once sourced, Orencia is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Orencia through NPP's regulated import pathway, with rheumatology and transplant specialists in major cities supporting the treatment process.
Leading rheumatology and transplant centers in Mumbai support Orencia treatment coordination.
Delhi's major hospitals assist patients with prescription support and documentation for Orencia.
Bangalore's specialist network offers access to Orencia for eligible autoimmune and transplant patients.
Chennai-based specialists coordinate Orencia access alongside comprehensive rheumatologic and transplant care.
Hyderabad's care institutions support patients pursuing Orencia therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Orencia.
Pune-based specialists assist with diagnosis confirmation and Orencia treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Orencia.
Kochi's specialist units assist patients with the documentation needed for Orencia access.
Chandigarh's care centers support Orencia treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Orencia access process.
Lucknow-based centers assist patients pursuing Orencia therapy.
Bhubaneswar's institutions support access to Orencia for eligible patients.
Guwahati's specialists help coordinate Orencia access for patients across the Northeast.
Patients in other cities across India can also access Orencia through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
